In this episode of The BioHub by Avetix, Model Medicines Co-Founder and CEO Daniel Haders II, Ph.D., discussed the company’s distinct approach to AI-native drug discovery and why it has deliberately taken a different path from many conventional AI drug discovery platforms. The conversation explored Model Medicines’ use of small but highly diverse datasets, large-scale inference, biological choke points, and program-level validation across oncology and infectious disease. Dr. Haders also shared the story behind the company’s formation, how the team thinks about prioritization and capital efficiency, and how GALILEO™ is being applied to drug discovery problems long considered difficult, “undruggable,” or impossible to solve.